Prescription medication · Rho Kinase Inhibitor / PGA Combination
netarsudil/latanoprost
Also sold as Rocklatan. Rocklatan is used to lower high pressure in your eyes.
Data updated 2026-05-15
- 1,191
- FDA reports
- 1
- InteractionFew interactions
- $131.84
- Brand price (NADAC)
What the data shows
netarsudil/latanoprost (Rocklatan) is a prescription Rho Kinase Inhibitor / PGA Combination, with 1,191 FDA adverse-event reports on file, with 1 documented drug interaction.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
netarsudil/latanoprost (Rocklatan) is a prescription Rho Kinase Inhibitor / PGA Combination. Rocklatan is used to lower high pressure in your eyes.
Rocklatan is an eye drop medicine that lowers pressure inside the eye. It is used for people with open-angle glaucoma or ocular hypertension.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$131.84/unit
Generic Available
No
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Rocklatan is used to lower high pressure in your eyes.
Common side effects
Redness of the eye (59%), Pain where the drop is applied (20%), Changes in the cornea (15%)
Key warnings
Rocklatan can cause changes in eye color, eyelid, and eyelashes.
The sections below are summarized in plain English from netarsudil/latanoprost's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Rocklatan contains two medicines that work together. One medicine helps to relax eye tissues to allow fluid to drain better. The other medicine helps to reduce the amount of fluid your eye makes. This combination lowers the pressure in your eye.
How to Take It
Use one drop of Rocklatan in the affected eye(s) once a day in the evening. Try to use the drops at the same time each evening. If you miss a dose, just continue with your next dose the following evening. Do not use Rocklatan more than once a day. If you use other eye drops, wait at least 5 minutes before using them.
This is a plain-language summary of netarsudil/latanoprost's FDA labeling, not individualized dosing advice. Ask a pharmacist or prescriber before changing how you take this medication.
Pregnancy & Breastfeeding
It is not known if Rocklatan will harm an unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if Rocklatan passes into breast milk. Discuss with your doctor if you are breastfeeding.
This is a plain-language summary of netarsudil/latanoprost's FDA labeling, not individualized advice. Ask a pharmacist or prescriber about pregnancy or breastfeeding on this medication.
Missed Dose
If you miss a dose of Rocklatan, continue with your next dose in the evening. Do not use a double dose to make up for the missed dose.
This is a plain-language summary of netarsudil/latanoprost's FDA labeling, not individualized advice. Ask a pharmacist or prescriber what to do about your specific missed dose.
Storage
Keep Rocklatan protected from light and refrigerated until opened. After opening, it can be stored at room temperature for up to 6 weeks, or refrigerated until the expiration date.
Side Effects (from patient reports)
Based on 1,191 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for netarsudil/latanoprost, by number of reports
- Redness of the eye
Redness of the eye
244 reports
- Blurred vision
Blurred vision
149 reports
- Eye pain
Eye pain
134 reports
- Eye redness
Eye redness
133 reports
- Eye irritation
Eye irritation
109 reports
- Swelling of the cornea 95
Swelling of the cornea
95 reports
- Increased pressure in the eye 88
Increased pressure in the eye
88 reports
- Reduced sharpness of vision 88
Reduced sharpness of vision
88 reports
- Increased tearing 87
Increased tearing
87 reports
- Eye itching 64
Eye itching
64 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Serious Warnings
Rocklatan can cause changes in eye color, eyelid, and eyelashes. The color change in the iris (colored part of the eye) may be permanent. Eyelash changes, like increased length and thickness, are usually reversible when you stop using Rocklatan. This medicine may also cause swelling in the cornea, especially if you have existing cornea problems or have had eye surgery. Tell your doctor if you have eye pain or vision changes.
Known Drug Interactions
The combined use of two or more prostaglandins or prostaglandin analogs including latanoprost ophthalmic solution 0.005% is not recommended.
Mechanism: Both drugs are in the same family and work the same way. Using more than one at a time can actually make them less effective at lowering eye pressure.
What to do: You should not use these two eye drops together. Your doctor will likely have you use just one of these medications.
This is a plain-language summary of interactions documented in FDA labeling, not individualized advice. Ask a pharmacist or prescriber before combining medications.
Common Questions
Can I use Rocklatan more than once a day to lower my eye pressure faster?
What should I do if I wear contact lenses?
How long does it take for Rocklatan to start working?
Can I use Rocklatan with other eye drops?
What if I accidentally get Rocklatan in my mouth?
Can Rocklatan cause my eyelashes to grow longer?
Will Rocklatan change my eye color?
What should I do if I experience eye pain or vision changes while using Rocklatan?
Can I drive or operate machinery after using Rocklatan?
How long can I use Rocklatan after opening the bottle?
What are the common side effects of netarsudil/latanoprost?
Does netarsudil/latanoprost interact with other medications?
What drug class is netarsudil/latanoprost?
Is netarsudil/latanoprost safe during pregnancy?
Related Medications in Rho Kinase Inhibitor / PGA Combination
Other drugs grouped near netarsudil/latanoprost - same-class peers and common alternatives.
aflibercept
Eylea
AHZANTIVE is a medicine used to treat certain eye problems.
Compare with netarsudil/latanoprost →
artificial tears
Refresh, Systane
Artificial tears are eye drops that lubricate your eyes.
Compare with netarsudil/latanoprost →
bevacizumab (ophthalmic)
Avastin
Avastin is a medicine that blocks a protein called vascular endothelial growth factor (VEGF).
Compare with netarsudil/latanoprost →
bimatoprost
Lumigan
Bimatoprost eye drops help lower pressure in the eye.
Compare with netarsudil/latanoprost →
brimonidine ophthalmic
Alphagan P
Alphagan P eye drops help lower pressure in the eye.
Compare with netarsudil/latanoprost →
Compare netarsudil/latanoprost vs aflibercept side-by-side →
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
Why some drugs demand precise dosing and monitoring
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on netarsudil/latanoprost
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for netarsudil/latanoprost
The FDA label for netarsudil/latanoprost (sold under brand names such as Rocklatan) classifies it as a prescription-only medication in the Rho Kinase Inhibitor / PGA Combination class. Rocklatan is used to lower high pressure in your eyes. Official labeling lists 4 commonly reported side effects, including Redness of the eye (59%), Pain where the drop is applied (20%), Changes in the cornea (15%).
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 1,191 voluntary reports. The database also lists 1 documented drug interaction derived from FDA labeling, with the top-flagged interaction rated moderate severity. NADAC pricing from CMS.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information further shape supply and switching decisions. This page summarizes public FDA data for educational purposes only and is not a substitute for professional medical advice, always consult a licensed healthcare provider before starting, stopping, or changing any medication.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. Always consult a healthcare professional before making medication decisions.
Last updated: January 20, 2026
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled and last refreshed May 2026. See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages